Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
01541 宜明昂科-B
Listing Date2023/09/05
Listing Price18.600
  • 14.800 +0.200 (+1.370%)    Sink Below Listing Price
  • 15-min delayed, last update: 27/05/2024 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    10 lot
  • One Lot Success Rate

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. founded in June 2015 in the PRC, it is a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies.


The Group have developed its Core Product, IMM01, an innovative clinical-stage CD47-targeted molecule. IMM01 is being developed for the treatment of various blood cancers and solid tumors in combination with other agents. Including IMM01, its pipeline consists of 14 drug candidates featured by a comprehensive innate-immunity-based asset portfolio targeting CD47 and other novel immune checkpoints, with eight ongoing clinical programs.


Its core business model is to in-house discover, develop and commercialize novel immuno-oncology therapies. It may also collaborate with third parties on the clinical development and commercialization of drug candidates. It is collaborating with Sunshine Guojian to conduct clinical trials evaluating a combination therapy using CIPTERBIN® (inetetamab, a HER2 mAb) and IMM01 for HER2-positive solid tumors in mainland China, and Sunshine Guojian will drive and fund relevant clinical trials.


As of 17 August 2023, the Group owned nine issued patents in the PRC, eight issued patents in the U.S.. In relation to its Core Product, IMM01, it owned one patent family, which includes one issued patent in the PRC, one issued patent in the U.S., one issued patent in the European Union (EU) and one issued patent in Japan.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares17.15M H shares
No. of International Offer Shares15.43M H shares
No. of HK Offer Shares1.71M H shares
Offer Price$18.60
Stock Code1541
Sponsor(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)Morgan Stanley Asia Limited, China International Capital Corporation Hong Kong Securities Limited, Fosun International Securities Limited, CMB International Capital Limited, BOCI Asia Limited, ICBC International Securities Limited, Soochow Securities International Brokerage Limited, Futu Securities International (Hong Kong) Limited
Application PeriodAug 24 (Thu) - noon, Aug 29 (Tue)
Price Determination Date--
Result Announcement DateOn or before Sep 04 (Mon)
Result Announcement DateOn or before Sep 04 (Mon)
Result Announcement DateOn or before Sep 04 (Mon)
Dealings in Shares commence onSep 05, 2023. (Tue)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$18.60
Capitalization (H Shares)4.23B
NAV / share ($)$2.75 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 18.6, the net proceeds raised would be HKD 233.40M, of which
40% : Used for ongoing and planned clinical trials, preparation for registration filings, and planned commercial launch of Core Product, IMM01 (SIRPα-Fc fusion protein)
28% : Used for ongoing and planned clinical trials, preparation for registration filings, and planned commercial launch of Key Products, IMM0306 (CD47×CD20), IMM2902 (CD47×HER2) and IMM2520 (CD47×PD-L1)
10% : Used for the planned clinical trial of IMM47 (CD24 mAb)
5% : Used for the ongoing clinical trials of IMM2510 (VEGF×PD-L1) and IMM27M (CTLA4 ADCC-enhanced mAb)
7% : Used for construction of our new manufacturing facility in Zhangjiang Science City, Shanghai
5% : Used for continuous preclinical research and development of multiple preclinical- and discovery-stage assets
5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.